research use only
Cat.No.S4095
|
In vitro |
DMSO
: 100 mg/mL
(196.63 mM)
Ethanol : 100 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 508.55 | Formula | C27H34F2O7 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 23674-86-4 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | CM 9155 | Smiles | CCCC(=O)OC1(CCC2C1(CC(C3(C2CC(C4=CC(=O)C=CC43C)F)F)O)C)C(=O)COC(=O)C | ||
| In vitro |
The difluprednate emulsion formulation begin by suspending DFBA in a variety of oils (castor, cottonseed, medium-chain fatty acid triglyceride, oleic, olive, peanut, and soybean). This compound's ophthalmic emulsion's active metabolite, 6α,9-difluoroprednisolone 17-butyrate (DFB), has the lowest Ki value (611 nM) for the glucocorticoid receptor and is significantly more active than prednisolone, which has a Ki value of 3.4 nM.
|
|---|---|
| In vivo |
Difluprednate emulsion is rapidly deacetylated in the aqueous humor to difluoroprednisolone butyrate (DFB) in rats and rabbits, the drug’s active metabolite, which has a similar corticosteroid activity profile. Radio-labeled this compound is instilled in the right eyes of pigmented rabbits in a separate study examining DFBA excretion. This emulsion (0.05%) results in higher aqueous humor concentrations than the suspension form in the eyes of rabbits. Its concentrations ≥0.01% shows a statistically significant inhibition of inflammation compared to saline in a rabbit model, with the anti-inflammatory response proceeding in a dose-dependent manner. It suppresses uveitis in all three concentration (0.002%, 0.01%, and 0.05%) in a dose-dependent manner in rats, and this compound 0.05% shows statistically superior anti-inflammatory activity compared to Betamethasone (0.1%).
|
References |
|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT00616993 | Completed | Inflammation |
Sirion Therapeutics Inc. |
January 2008 | Phase 3 |
| NCT00616070 | Completed | Inflammation |
Sirion Therapeutics Inc. |
December 2007 | Phase 3 |
| NCT00407225 | Completed | Inflammation |
Sirion Therapeutics Inc. |
December 1999 | Phase 2 |
| NCT00430092 | Completed | Inflammation |
Sirion Therapeutics Inc. |
Phase 3 | |
| NCT00429923 | Completed | Inflammation |
Sirion Therapeutics Inc. |
Phase 3 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.